96 related articles for article (PubMed ID: 15492266)
1. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
[TBL] [Abstract][Full Text] [Related]
2. Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.
Rudek MA; Chang CY; Steadman K; Johnson MD; Desai N; Deeken JF
Cancer Chemother Pharmacol; 2014 Apr; 73(4):729-36. PubMed ID: 24488374
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling.
Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Takeuchi S; Koeffler HP; Taguchi H
Cancer Sci; 2005 Jul; 96(7):425-33. PubMed ID: 16053514
[TBL] [Abstract][Full Text] [Related]
4. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.
Sevrioukova IF; Poulos TL
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18422-7. PubMed ID: 20937904
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer.
Li Q; Xu J; He Z; Wen X; Wang F; Zhang P; Li J; Song B; Wang Q; Li R; Huang H
Cancer Manag Res; 2019; 11():10125-10133. PubMed ID: 31819645
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel.
Zhou Y; Yang J; Zhang R; Kopeček J
Eur J Pharm Biopharm; 2015 Jan; 89():107-15. PubMed ID: 25481033
[TBL] [Abstract][Full Text] [Related]
7. Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis.
Lu Y; Zhang X; Beheshti B; Zhang J
Prostate; 2009 Feb; 69(3):234-48. PubMed ID: 19016247
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.
Hillowe A; Gordon C; Wang L; Rizzo RC; Trotman LC; Ojima I; Bialkowska A; Kaczocha M
PLoS One; 2023; 18(10):e0292483. PubMed ID: 37796964
[TBL] [Abstract][Full Text] [Related]
9. Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.
Li Y; Malaeb BS; Li ZZ; Thompson MG; Chen Z; Corey DR; Hsieh JT; Shay JW; Koeneman KS
Prostate; 2010 May; 70(6):616-29. PubMed ID: 20043297
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer.
Ranjan A; Benjamin CJ; Negussie AH; Chokshi S; Chung PH; Volkin D; Yeram N; Linehan WM; Dreher MR; Pinto PA; Wood BJ
Pharm Res; 2016 Oct; 33(10):2459-69. PubMed ID: 27343000
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.
Nalairndran G; Chung I; Abdul Razack AH; Chung FF; Hii LW; Lim WM; Looi CK; Mai CW; Leong CO
J Cell Mol Med; 2021 Sep; 25(17):8187-8200. PubMed ID: 34322995
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent.
Bijnsdorp IV; Kruyt FA; Gokoel S; Fukushima M; Peters GJ
Cancer Sci; 2008 Nov; 99(11):2302-8. PubMed ID: 18957056
[TBL] [Abstract][Full Text] [Related]
13. Combination of Kaempferol and Docetaxel Induces Autophagy in Prostate Cancer Cells In Vitro and In Vivo.
Zhou Q; Fang G; Pang Y; Wang X
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833967
[TBL] [Abstract][Full Text] [Related]
14. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy.
Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Kanga N; Zhang JY; Chen X; Wouters BG; Tannock IF
Br J Cancer; 2015 Mar; 112(5):832-40. PubMed ID: 25647012
[TBL] [Abstract][Full Text] [Related]
15. In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer.
Rushworth LK; Harle V; Repiscak P; Clark W; Shaw R; Hall H; Bushell M; Leung HY; Patel R
Life Sci Alliance; 2020 Dec; 3(12):. PubMed ID: 33033111
[TBL] [Abstract][Full Text] [Related]
16. The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice.
Denslow A; Switalska M; Nowak M; Maciejewska M; Chlopicki S; Marcinek A; Gebicki J; Wietrzyk J
BMC Cancer; 2017 Mar; 17(1):177. PubMed ID: 28270133
[TBL] [Abstract][Full Text] [Related]
17. Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells.
Li X; Lu J; Kan Q; Li X; Fan Q; Li Y; Huang R; Slipicevic A; Dong HP; Eide L; Wang J; Zhang H; Berge V; Goscinski MA; Kvalheim G; Nesland JM; Suo Z
Sci Rep; 2017 Jul; 7(1):5081. PubMed ID: 28698547
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4.
Ghiaur G; Valkenburg KC; Esteb C; Ambinder A; Imus PH; Pienta KJ; Jones RJ
Cancer; 2023 Jun; 129(11):1744-1751. PubMed ID: 36840972
[TBL] [Abstract][Full Text] [Related]
19. Friedelin, a novel inhibitor of CYP17A1 in prostate cancer from
Joshi BP; Bhandare VV; Vankawala M; Patel P; Patel R; Vyas B; Krishnamurty R
J Biomol Struct Dyn; 2023 Nov; 41(19):9695-9720. PubMed ID: 36373336
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
